Zarnestra Phase III Trial May Lack Sufficient Power To Show Survival Benefit
Executive Summary
An ongoing Phase III trial of Johnson & Johnson's acute myeloid leukemia therapy Zarnestra may lack sufficient power to show a survival benefit, the FDA Oncologic Drugs Advisory Committee biostatistician suggested May 6
You may also be interested in...
Can Tricky Elderly AML Population Justify Weak Data? Fate Of Genzyme's Clolar and Vion's Onrigin Rests With ODAC
FDA's briefing documents for the Sept. 1 review suggest the single-arm Phase II trials are not sufficient; the wild card will be whether the panel thinks better trials can be done in that population.
J&J Risperdal Sales Climb; Pricing Relative To Invega Depends On Dose
Johnson & Johnson's blockbuster atypical antipsychotic Risperdal (risperidone) shows no signs of slowing growth a year before the drug is scheduled to lose patent protection
J&J Risperdal Sales Climb; Pricing Relative To Invega Depends On Dose
Johnson & Johnson's blockbuster atypical antipsychotic Risperdal (risperidone) shows no signs of slowing growth a year before the drug is scheduled to lose patent protection